中国医学科学院药物研究所-九游官网下载

唐克，博士，副研究员。2007年毕业于中国药科大学药学专业，获学士学位；2014年毕业于北京协和医学院药物研究所药理学专业，获博士学位。主持国家自然科学基金等3项基金，参与十一五、十二五、十三五“重大新药创制”国家科技重大专项及省部级课题4项。研究成果获授权专利11项，发表多篇研究性论文。

1、治疗特应性皮炎的新药发现及机制研究。
2、抗病毒药效学评价（流感病毒、hiv、hcv、呼吸道合胞病毒等）。

近5年代表性成果：
1. chen s#, xin y#, tang k, wu y, guo y*. nardosinone and aurantio-obtusin, two medicine food homology natural compounds, are anti-influenza agents as indicated by transcriptome signature reversion. phytomedicine. 2023,108:154515.
2. tang k#, wu y#, chen s, xin y, guo y*. discovery of the anti-influenza a virus activity of sb216763 and cyclosporine a by mining infected cells and compound cellular signatures. chin chem lett. 2022,33(5):2541-2544.
3. xin y#, chen s#, tang k, wu y, guo y*. identification of nifurtimox and chrysin as anti-influenza virus agents by clinical transcriptome signature reversion. int. j. mol. sci. 2022, 23(4):2372.
4. tang k#, zhang x#, guo y*. identification of the dietary supplement capsaicin as an inhibitor of lassa virus entry. acta pharm sin b, 2020,10(5):789-798.
5. zhang x, tang k, guo y*. the antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-gp2 subunit interface of lassa virus glycoprotein. antiviral res. 2020,174:104701.
6. chen q, tang k, guo y*. discovery of sclareol and sclareolide as filovirus entry inhibitors. j asian nat prod res. 2020,22(5):464-473.
7. zhang x#, yan f#, tang k, chen q, guo j, zhu w, he s, banadyga l, qiu x*, guo y*. identification of a clinical compound losmapimod that blocks lassa virus entry. antiviral res. 2019, 167: 68-77.

授权专利11项（授权公告号：cn 107149602b、cn 107149603 b、cn 107176921 b、cn 107151231 b、cn 107174581 b、cn107151223b等）